Departmental Research Funding
Cheung B (PI), Gangestad AK, The Appearance of Cesarean Section Wounds by Ultrasound Imaging, 2005 – ongoing, Biomet Orthopedics, Inc.
Cheung B (PI), Gangestad AK, The Effects of Autologous Platelet Gel Use at Cesarean Section Closure on Postoperative Wound Healing and Recovery, 2005 – ongoing, Biomet Orthopedics, Inc.
Colby K (PI), Waggoner, SE (Medical Advisor), Patient Navigator Video Training for Cancer in Low-Income African Americans, #1R43CA124328-01, National Cancer Institute, total budget $99,643, Pending
Colby K (PI), Waggoner, SE (Medical Advisor), Latino Faith-Based Cancer Outreach, R44 CA101557, NCI, total budget $783,896, Pending
Gass M (PI), Liu JH, Clinical Centers for the Clinical Trial and Observational Study of the Women's Health Initiative – East, 09/30/94 - 09/14/05, NIH, Direct Costs: $10,428,075.
Gass M (PI), Liu JH, Women’s Health Initiative Memory Study (WHIMS), 09/30/94 -09/14/05, NIH, Direct Costs: $212,070.
Gorodeski, G (PI), Estrogen and aging effects on transvaginal transport, 06/01/99– 05/31/08, NIH RO1 AG01595506, Direct Costs: $1,250,000.
Greenfield, M (PI), Lazebnik N, The effects of chemotherapy on ovarian structure and function, General Clinical Research Center (Horowitz R, PI), 01/01/04 – 12/31/05, NIH, M01 RR000080-42, Direct Costs: $9,318.
Herbst A (PI), Waggoner, SE, Continuation of Follow-up of DES-Exposed Cohorts, 2000-2005, NIH/NCI N01 CP 51018, $163,300.
Janata J (Co-PI) A controlled study of an interdisciplinary pain management approach led by primary care physicians, The 4PCP trial (Primary Practice Program for Patients with Chronic Pain). The Josiah Macy Foundation. $983,076, 2004-2007.
Kingsberg S (PI), Liu JH, Arredondo FA, A Study to Evaluate the Efficacy and Safety of Transdermal Patches Delivering Hormone Therapy in Menopausal Women with Low Libido, 7/19/2004 – ongoing, Proctor and Gamble Pharmaceuticals, $61,497.
Kingsberg S (PI), Liu JH, Gangestad AK, A Trial of the Efficacy and Safety of Pharmalogical Therapy in Women with Mixed Desire/Interest/Arousal/Orgasm Disorders, Zestra Laboratories, $30,450, Pending.
Kingsberg, S (PI), Arredondo FA A Trial To Compare The Effects Of Hormone Therapy On The Vaginal Bleeding Pattern, Sexual Desire and Arousal in Postmenopausal Women with Sexual Dysfunction, Organon. 07/28/04 – 12/31/05, $112,500.
Kinsella T (PI), Waggoner, SE (Co-PI), Phase I/II Trial of intravenous TRIAPINE (NSC # 663249) in combination with pelvic radiation therapy and with or without weekly intravenous Cisplatin chemotherapy for locally advanced cervical cancer or pelvic gynecologic malignancy, 2005 – ongoing, NCI Division of Cancer Treatment and Diagnosis (CTEP), Direct Costs: $67,610.
Liu JH (PI), A Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile Hormone Administered Intravenously or Subcutaneously in Anovulatory or Oligoovulatory Infertile Females, 1/19/05 - 12/31/05, Ferring Pharmaceuticals, $58,494.
Liu JH (PI), Arredondo FA, Gangestad AK, A Comparison of Multiple Doses of Hormones in Combination and Alone, in Relieving Vasomotor Symptoms in Postmenopausal Women - 8/12/05 – 12/31/05, Solvay Pharmaceuticals, $95,250.
Liu JH (PI), Arredondo FA, A Trial to Demonstrate the Safety and Efficacy of Daily Hormone for the Treatment of Vasomotor Symptoms in Postmenopausal Women, 11/17/05 – 12/31/05, Duramed Research, $75,000.
Liu JH (PI), Arredondo FA, A Trial to Evaluate the Efficacy and Safety of Synthetic Hormone for the Treatment of Vulvovaginal Atrophy in Healthy Postmenopausal Women, 3/16/05 – 12/31/05, Duramed Research, $104,625.
Liu JH. (PI), Kingsberg S, A Phase III Study to Evaluate the Efficacy and Safety of Transdermal Hormone Therapy in Women with Hypoactive Sexual Desire Disorder, 6/20/02 – ongoing, Proctor and Gamble Pharmaceuticals, $102,952.
Liu JH. (PI), Kingsberg S, A Phase III Study to Evaluate the Efficacy and Safety of Transdermal Hormone Therapy Naturally Menopausal Women with Hypoactive Sexual Desire Disorder, 6/20/02 – ongoing, Proctor and Gamble Pharmaceuticals, $131,425.
Liu JH (PI), Loret de Mola, JR, Arredondo FA, Gangestad AK, Clinical Contraceptive Trials Network-Female, 04/01/04 - 03/31/10, NIH, Direct Costs: $3,900,000.
Mesiano, S (PI), Interaction Between Progesterone and Estrogen in the Control of Human Parturition, 06/01/05 – 05/31/08; March of Dimes, Direct Costs: $219,254.
Mesiano, S (PI), Myometrial PRs/ERs: Targets for the Prevention of Preterm Labor, 2/01/06 – 1/31/08, NIH R03 HD051563, Direct Costs: $100,000
Prokopczyk B (PI), Waggoner, SE, The Role of Polyaromatic Hydrocarbons and Tumor Specific Nitrosamines in Cervical Cancer. Project 4 Tobacco Carcinogenesis and Chemoprevention, 2001-2005, NIH PO1 CA70972, $2,122,872 ($45,379/ yr. for Case Western Reserve Subcontract).
Rote, N (PI), Antiphospholipid Antibody Heterogeneity, 7/1/03 – 4/30/08, NIH, RO1 HD043566-01A1, $1,125,000 in Direct Costs
Rote, N (PI), Antibody-directed Targeting of Ovarian Cancer Blood Vessels, 03/15/06 – 03/14/08, OROC (Out Run Ovarian Cancer) Advocacy and Research Group, $26,000 in Direct Costs
Rote, N (PI), Placental Endogenous Retrovirus Expression, 2/1/03 – 1/31/06, NIH, RO3 HD043546-(01-02), $100,000 in Direct Costs
Rote, N (PI), Trophoblast Intercellular Fusion, 4/1/08 – 3/31/10, NIH, R21 HD052803, $275,000 in Requested Direct Costs, Pending
Rote, N (PI), Apoptosis and Cytotrophoblast Differentiation, 4/1/08 – 3/31/11, NIH, RO1, $750,000 in Requested Direct Costs, Pending
Rote, N (PI), Pathophysiology of Antiphospholipid Antibodies, 7/1/08 – 06/30/13, NIH, RO1 HD054693-01, $1,250,000 in Requested Direct Costs, Pending
Van Buren, G (PI), A Study to Assess the Efficacy, Safety, and Tolerance of Hormone Gels in Preventing Preterm Delivery in Pregnant Women at Increased Risk for Preterm Delivery, 4/1/04 – present. Columbia Labs, $225,300.
von Gruenigen, VE (PI), Lifestyle Change and Quality of Life in Obese Endometrial Cancer Survivors, 01/01/05 -12/31/06, Lance Armstrong Foundation, Direct Costs: $110,000.
von Gruenigen, VE (PI), Support of the Gynecologic Cancer Patient, 04/01/04 -04/31/05, Stark County Community Foundation, Direct Costs: $10,000.
von Gruenigen, VE (PI), The Recurrence of Early Endometrial Cancer in the Obese Patient, GOG/NCI, Pending.
von Gruenigen, VE (PI), A Phase II Trial of Carboplatin and Paclitaxel in Elderly Women with Ovarian Cancer, GOG/ NCI, Pending.
von Gruenigen, VE (PI), A Phase II randomized trial of BAY 43-9006, a Novel Raf Kinase Inhibitor, 2004-2005, NCI, Protocol # 6557.
von Gruenigen, VE (PI), Strategies to Improve the Quality of Life in Ovarian Cancer, 2005 – 2006, Gynecologic Cancer Foundation and Ovarian Cancer Research Grant, $25,000.
von Gruenigen, VE (PI), Waggoner SE, A Trial For the Prevention of Doxil – related Palmar – Plantar Erythrodysesthesia, 2004 – ongoing, Therapeutics Division of Ortho-Biotech, Direct Costs: $120,000.
Waggoner, SE (PI), von Gruenigen, VE (Co-PI), A Trial of Intravenous Medication as Post Chemotherapy Consolidation (Project 4 in Program for Ovarian, Fallopian tube and Peritoneal Carcinomas), 2002 – 2006, Unither Pharmaceuticals, Per capita reimbursement $8,896.
Waggoner, SE (PI), Smoking Cessation Intervention for Women with Locally Advanced Cervical Carcinoma: A Pilot Study. NCI Division of Cancer Prevention, Pending.
Waggoner, SE (PI), GOG Clinical Trials, NIH CA27469-94, 7/1/04 – 3/21/07, $100,000 per year average direct costs.
Wilson M (PI), Liu JH, Development and Application of a Drug Delivery Device, 07/01/01 07/01/04, NIH SBIR Phase II Grant, Direct Costs: $748,300.
Zanotti KM, Monk B. An Evaluation of Combined Therapy with Growth Factor Support in the Third Lline Treatment of Recurrent or Persistent Oovarian or Primary Peritoneal Cancer. 2005-ongoing, GOG Protocol 0186.
|
